Overview

Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Status:
ENROLLING_BY_INVITATION

Trial end date:
2028-05-01

Target enrollment:

Participant gender:

Summary

Aim of this study will evaluate the efficacy and safety of Polatuzumab Vedotin and Zanubrutinib in combination with R-CHP for newly diagnosed untreated Non-GCB DLBCL Patients with extranodal involvement.

Phase:

PHASE2

Details

Lead Sponsor:

The First Affiliated Hospital of Soochow University

Treatments:

Cyclophosphamide
Doxorubicin
polatuzumab vedotin
Prednisone
Rituximab
zanubrutinib